The company seeks to expand the use of Opdivo to patients with locally advanced unresectable or metastatic urothelial carcinoma (mUC) that has progressed on or after platinum-containing therapy. The
One study showed that people with VTE taking XARELTO® for longer than three months had a lower risk of VTE recurrence, without an increase in major bleeding, compared
The recently initiated Phase II study is the first clinical investigation of SNF472 in patients with newly diagnosed calciphylaxis. Designed as an open-label investigation, eligible patients will be
Under the agreement, NBE and Sotio will collaborate on the discovery, non-clinical development and manufacturing of novel ADC products against undisclosed targets. The ADC products will be based on
The compound, named RXC005, has the potential to treat the majority of patients suffering from Chronic Lymphocytic Leukaemia (CLL), including those who become resistant to the increasingly used
The study enrolled 540 subjects who received letermovir once daily either in an oral tablet or intravenous formulation. Therapy was begun as early as the same day as
LARTRUVO's indication is approved under Accelerated Approval, and is based on data from the Phase 2 portion of the pivotal JGDG trial. Continued approval for this indication may
LIMT HDV is a 30-patient study designed to evaluate the safety, tolerability and efficacy of two dose levels of Lambda after 48 weeks of treatment. LIMT HDV is
SOBI003 will be included in the EU Community Register of Orphan Medicinal Products. MPS IIIA or Sanfilippo A syndrome is an inherited systemic lysosomal storage disease with a
It is the second collaboration between both the parties focusing on dengue. The first one was related to the development of a botanical drug to treat dengue. The
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.